Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 May 2010

Boige Valérie, Mendiboure Jean, Pignon Jean-Pierre, Loriot Marie-Anne, Castaing Marine, Barrois Michel, Malka David, Trégouët David-Alexandre, Bouché Olivier, Le Corre Delphine, Miran Isabelle, Mulot Claire, Ducreux Michel, Beaune Philippe, Laurent-Puig Pierre

Abstract excerpt

PURPOSE: The aim was to investigate whether germline polymorphisms within candidate genes known or suspected to be involved in fluorouracil (FU), oxaliplatin, and irinotecan pathways were associated with toxicity and clinical outcome in patients with metastatic colorectal cancer (mCRC). PATIENTS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Camptothecin
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to Irinotecan

Share to Leucovorin

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Pharmacogenetics

Source

Identifiers

PMID: 20385995
DOI: 10.1200/JCO.2009.25.2106

Genes

ERCC2
GSTT1
MTHFR
ERCC1
GSTM1
GSTP1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20385995-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.PMID 20385995Read ↗

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.Semantic proximity Read ↗

Use of a Comprehensive Panel of Biomarkers to Predict Response to a Fluorouracil–Oxaliplatin Regimen in Patients with Metastatic Colorectal CancerSemantic proximity Read ↗

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.Semantic proximity Read ↗

Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.Semantic proximity Read ↗

A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.Semantic proximity Read ↗

Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patientsSemantic proximity Read ↗

Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische OnkologieSemantic proximity Read ↗

Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741.Semantic proximity Read ↗

Polymorphisms of GSTP1, ERCC2 and TS-3′UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patientsSemantic proximity Read ↗

FOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapy.Semantic proximity Read ↗

Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS TrialSemantic proximity Read ↗

UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.